Advertisement
Screener

GoodRx Holdings, Inc. (GDRX) Share buybacks

GoodRx Holdings, Inc. (GDRX) Share buybacks

  • Total buybacks · last 12 months (USD): Value $85.00M; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
  • Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..

Share buybacks

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Total buybacks · last 12 months (USD)$85.00MTrailing-year cash paid for share repurchases. Period ending 2026-06-30.
Buyback yield · 12 months(m)Cash paid for share repurchases / current market cap. Period ending 2026-06-30.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Buybacks · 12 months85.00M USDPayments for Repurchase of Common Stock
Market cap(m)

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingTotal buybacksMarket cap (USD)Buyback yield
2026-06-30$85.00M(m)(m)
2026-03-31$129.04M(m)(m)
2025-12-31$216.37M(m)(m)
2025-09-30$207.13M(m)(m)
2025-06-30$151.51M(m)(m)
2025-03-31$105.52M(m)(m)
2024-12-31$158.84M(m)(m)
2024-09-30$236.48M(m)(m)
2024-06-30$238.76M(m)(m)
2024-03-31$247.68M(m)(m)
2023-12-31$103.97M(m)(m)
2023-09-30$26.15M(m)(m)
2023-06-30$36.39M(m)(m)
2023-03-31$27.47M(m)(m)
2022-12-31$101.72M(m)(m)
2022-09-30(m)(m)(m)
2022-06-30(m)(m)(m)
2022-03-31(m)(m)(m)
2021-12-31$0.00(m)(m)
2021-09-30(m)(m)(m)
2021-06-30(m)(m)(m)
2021-03-31(m)(m)(m)
2020-12-31$0.00(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.